These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29175174)

  • 1. Doxycycline, a Well-Tolerated, Economic, and Effective Alternative for the First-Line Treatment of Bullous Pemphigoid.
    Morgado-Carrasco D; Riquelme-Mac Loughlin C; Fustà-Novell X; Iranzo P
    Actas Dermosifiliogr (Engl Ed); 2018; 109(6):549-550. PubMed ID: 29175174
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
    Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
    Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial.
    Mason JM; Chalmers JR; Godec T; Nunn AJ; Kirtschig G; Wojnarowska F; Childs M; Whitham D; Schmidt E; Harman K; Walton S; Chapman A; Williams HC;
    Br J Dermatol; 2018 Feb; 178(2):415-423. PubMed ID: 28940316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial.
    Chalmers JR; Wojnarowska F; Kirtschig G; Nunn AJ; Bratton DJ; Mason J; Foster KA; Whitham D; Williams HC;
    Br J Dermatol; 2015 Jul; 173(1):227-34. PubMed ID: 25683592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bullous pemphigoid: clinical practice guidelines.
    Fuertes de Vega I; Iranzo-Fernández P; Mascaró-Galy JM
    Actas Dermosifiliogr; 2014 May; 105(4):328-46. PubMed ID: 23540594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonbullous pemphigoid treated with doxycycline monotherapy: report of 4 cases.
    Safa G; Darrieux L
    J Am Acad Dermatol; 2011 Jun; 64(6):e116-8. PubMed ID: 21571156
    [No Abstract]   [Full Text] [Related]  

  • 7. Doxycycline, an Antibiotic or an Anti-Inflammatory Agent? The Most Common Uses in Dermatology.
    Navarro-Triviño FJ; Pérez-López I; Ruiz-Villaverde R
    Actas Dermosifiliogr (Engl Ed); 2020 Sep; 111(7):561-566. PubMed ID: 32401726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore.
    Goon AT; Tan SH; Khoo LS; Tan T
    Singapore Med J; 2000 Jul; 41(7):327-30. PubMed ID: 11026799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment with doxycycline and nicotinamide of two cases of persistent pemphigoid gestationis.
    Amato L; Coronella G; Berti S; Gallerani I; Moretti S; Fabbri P
    J Dermatolog Treat; 2002 Sep; 13(3):143-6. PubMed ID: 12227878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological advances in pemphigoid.
    Maglie R; Hertl M
    Curr Opin Pharmacol; 2019 Jun; 46():34-43. PubMed ID: 30769277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [EFFECTIVE TREATMENT FOR BULLOUS PEMPHIGOID WITH OMALIZUMAB].
    Neumark M; Tal Y; Zlotogorski A; Molho-Pessach V
    Harefuah; 2020 Jan; 159(1):29-30. PubMed ID: 31930804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxycycline in the treatment of bullous pemphigoid: as good as systemic corticosteroids?
    Hofmann SC
    Br J Dermatol; 2015 Jul; 173(1):17-8. PubMed ID: 26174646
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of generalized bullous pemphigoid with oral tetracycline.
    Sánchez Miralles E; Nuñez Cabezón M; Ledo Pozueta A
    J Am Acad Dermatol; 1994 Feb; 30(2 Pt 1):291. PubMed ID: 8288800
    [No Abstract]   [Full Text] [Related]  

  • 14. Usefulness of a Simple Immunohistochemical Staining Technique to Differentiate Anti-p200 Pemphigoid From Other Autoimmune Blistering Diseases: A Report of 2 Cases.
    García-Díez I; Martínez-Escala ME; Ishii N; Hashimoto T; Mascaró Galy JM; Pujol RM; Herrero-González JE
    Actas Dermosifiliogr; 2017; 108(1):e1-e5. PubMed ID: 27095685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.
    Santi CG; Gripp AC; Roselino AM; Mello DS; Gordilho JO; Marsillac PF; Porro AM
    An Bras Dermatol; 2019 Apr; 94(2 Suppl 1):33-47. PubMed ID: 31166405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid.
    Kasperkiewicz M; Hoppe U; Zillikens D; Schmidt E
    Clin Exp Dermatol; 2010 Aug; 35(6):614-7. PubMed ID: 19874345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is a pragmatic clinical trial?
    Williams HC; Burden-Teh E; Nunn AJ
    J Invest Dermatol; 2015 Jun; 135(6):1-3. PubMed ID: 25964272
    [No Abstract]   [Full Text] [Related]  

  • 18. Association between bullous pemphigoid and neurologic diseases: a case-control study.
    Casas-de-la-Asunción E; Ruano-Ruiz J; Rodríguez-Martín AM; Vélez García-Nieto A; Moreno-Giménez JC
    Actas Dermosifiliogr; 2014 Nov; 105(9):860-5. PubMed ID: 25004905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bullous pemphigoid in adolescence.
    Patsatsi A; Kyriakou A; Werth VP
    Pediatr Dermatol; 2019 Mar; 36(2):184-188. PubMed ID: 30569520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta-analysis.
    Jin XX; Wang X; Shan Y; Li SZ; Xu Q; Jin HZ; Zuo YG
    Arch Dermatol Res; 2022 Mar; 314(2):191-201. PubMed ID: 33774726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.